切换至 "中华医学电子期刊资源库"
高级检索
中华实验和临床感染病杂志(电子版)

中华实验和临床感染病杂志(电子版) ›› 2016, Vol. 10 ›› Issue (02) : 146 -150. doi: 10.3877/cma.j.issn.1674-1358.2016.02.004

临床论著

HBsAg定量在慢性乙型肝炎患者干扰素抗病毒治疗中的变化及临床意义
张楠1, 颜学兵2,†(), 郝俊贵2, 张言超2   
  1. 1. 214000　无锡市，江苏省无锡市第二人民医院重症医学科
    2. 221002　徐州市；徐州医学院附属医院感染性疾病科
  • 收稿日期:2015-06-02 出版日期:2016-04-15
  • 通信作者: 颜学兵
  • 基金资助:
    国家自然科学基金项目(No. 81371867); 江苏省"科教兴卫"医学重点人才培养基金(No.RC2011117)

Changes and clinical significance of quantitative hepatitis B surface antigen in patients with chronic hepatitis B receiving interferon therapy

Nan Zhang1, Xuebing Yan2,†(), Jungui Hao2, Yanchao Zhang2   

  1. 1. Intensive Care Unit, Wuxi No.2 People’s Hospital, Wuxi 214000, China
    2. Department of Infectious Diseases, the Afflicted Hospital of Xuzhou Medical College, Xuzhou 221002, China
  • Received:2015-06-02 Published:2016-04-15
  • Corresponding author: Xuebing Yan
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

张楠, 颜学兵, 郝俊贵, 张言超. HBsAg定量在慢性乙型肝炎患者干扰素抗病毒治疗中的变化及临床意义[J]. 中华实验和临床感染病杂志(电子版), 2016, 10(02): 146-150.

Nan Zhang, Xuebing Yan, Jungui Hao, Yanchao Zhang. Changes and clinical significance of quantitative hepatitis B surface antigen in patients with chronic hepatitis B receiving interferon therapy[J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2016, 10(02): 146-150.

目的

研究HBsAg定量在慢性乙型肝炎患者干扰素抗病毒治疗期间的变化及临床意义。

方法

收集43例接受IFN-α治疗的HBeAg阳性慢性乙型肝炎患者为研究对象。分别在治疗前和治疗后1、3和6个月时定量检测患者血清HBsAg水平；并同时监测其HBV DNA、HBeAg、HBcAb及ALT的水平。

结果

43例患者治疗前和治疗后1、3、6个月时血清HBsAg水平呈下降趋势，差异具有统计学意义（P = 0.029）；治疗1个月时较治疗前有所下降，但差异无统计学意义（t =-1.12、P = 0.304）；治疗3个月和6个月时均较治疗前显著下降，差异具有统计学意义（t =-2.71、P = 0.015，t =-2.71、P = 0.010）；其他不同时间点间比较差异均无统计学意义。IFN-α治疗6个月时患者血清HBsAg下降> 0.5 log10IU/ml组患者ALT复常率高于下降< 0.5 log10IU/ml组，差异具有统计学意义（χ2 =5.536、P = 0.019）；下降> 0.5 log10IU/ml组HBeAg阴转率高于下降< 0.5 log10IU/ml组，差异具有统计学意义（χ2 = 4.226、P = 0.040）；下降> 0.5 log10IU/ml组HBeAg血清学转换率高于下降< 0.5 log10IU/ml组，差异具有统计学意义（χ2 = 4.226、P = 0.040）。

结论

HBsAg定量在慢性乙型肝炎患者IFN-α治疗早期呈下降趋势。HBsAg定量在慢性乙型肝炎IFN-α治疗早期下降迅速的患者ALT复常率、HBeAg阴转率及HBeAg血清学转换率均高于下降缓慢者。

关键词: 表面抗原, 肝炎病毒, 乙型, 丙氨酸氨基转氨酶, e抗原, 肝炎病毒, 乙型, 血清学转换
Objective

To investigate the changes and clinical significance of quantitative hepatitis B surface antigen (HBsAg) in patients with chronic hepatitis B (CHB) receiving interferon-α (IFN-α) therapy.

Methods

Total of 43 CHB patients with HBeAg-positive who received IFN-α therapy were enrolled. The levels of serum HBsAg were detected before treatment and after 1 month, 3 months and 6 months respectively; while the levels of HBV DNA, HBeAg, HBcAb and ALT were monitored, respectively.

Results

The levels of serum HBsAg decreased during the IFN-α therpy, with significant difference (P = 0.029); the level of HBsAg at 1 month after treatment was lower than the baseline, but with no significant difference (t =-1.12, P = 0.304); the level of HBsAg at 3 and 6 months after treatment were lower than the baseline, with significant differences (t =-2.71, P = 0.015; t =-2.71, P = 0.010); there were no significant difference between other time points (P all > 0.05). After 6 months treatment, the patients with a reduction of HBsAg > 0.5 log10IU/ml achieved higher ALT normalization rate (χ2 =5.536, P = 0.019), HBeAg loss rate (χ2 = 4.226, P = 0.040) and HBeAg seroconversion rate (χ2 = 4.226, P = 0.040) than the rest patients with a reduction of HBsAg < 0.5 log10IU/ml.

Conclusions

The levels of serum HBsAg in patients with CHB decreased during IFN-α early treatment. The patients whose serum HBsAg decreased faster had higher ALT normalization rates, HBeAg loss rates and HBeAg seroconversion rates than the other ones.

Key words: Hepatitis B surface antigen, Alanine Transaminase, Hepatitis B e antigen, Seroconversion
表1 患者接受IFN-α治疗前的基线特征
指标 血清HBsAg 统计量 P值
下降> 0.5 log10IU/ml（n = 14） 下降< 0.5 log10IU/ml（n = 29）
性别（男/女）a 11/3 19/10 — 0.491
家族史（有/无） 6/8 13/16 χ2 = 0.015 0.903
年龄（±s，岁） 29.6 ± 9.8 29.4 ± 7.7 t = 0.071 0.944
ALT（±s，U/L） 126.4 ± 65.9 121.2 ± 84.7 t = 0.348 0.729
HBV DNA（±s，log10IU/ml） 6.75 ± 1.08 6.72 ± 0.99 t = 0.065 0.948
HBsAg（±s，log10IU/ml） 3.96 ± 0.55 3.81 ± 0.46 t = 0.958 0.344
HBeAg（±s，PEIU/ml） 267.74 ± 193.21 200.03 ± 177.33 t = 1.094 0.280
HBcAb（±s，S/CO） 10.73 ± 2.39 10.23 ± 2.11 t = 1.171 0.248
表2 患者接受IFN-α治疗6个月时的治疗应答[例（%）]
指标 血清HBsAg χ 2值 P值
下降> 0.5 log10IU/ml（n = 14） 下降< 0.5 log10IU/ml（n = 29）
ALT复常 12（85.7） 14（48.3） 5.536 0.019
HBV DNA低于检测下限a 5（35.7） 9（31.0） 0.000 1.000
HBeAg阴转a 6（42.9） 3（10.3） 4.226 0.040
HBeAg血清学转换a 6（42.9） 3（10.3） 4.226 0.040
[1]
Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences[J]. N Engl J Med,2004,350(11):1118-1129.
[2]
Hoofnagle JH, Doo E, Liang TJ, et al. Management of hepatitis B: summary of a clinical research workshop[J]. Hepatology,2007,45(4):1056-1075.
[3]
European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection[J]. J Hepatol,2012,57(1):167-185.
[4]
Brunetto MR. A new role for an old marker, HBsAg[J]. J Hepatol,2010,52(4):475-477.
[5]
Chan HL, Thompson A, Martinot-Peignoux M, et al. Hepatitis B surface antigen quantification: why and how to use it in 2011-a core group report[J]. J Hepatol,2011,55(5):1121-1131.
[6]
中华医学会肝病学分会和感染病学分会. 慢性乙型肝炎防治指南(2010)年版[J]. 中华肝脏病杂志,2011,19(1):13-24.
[7]
Bowden S. Serological and molecular diagnosis[J]. Semin Liver Dis,2006,26(2):97-103.
[8]
Chan HL, Wong VW, Tse AM, et al. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response[J]. Clin Gastroenterol Hepatol,2007,5(12):1462-1468.
[9]
Rijckborst V, Hansen BE, Cakaloglu Y, et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels[J]. Hepatology,2010,52(2):454-461.
[10]
Sonneveld MJ, Rijckborst V, Boucher CA, et al. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline[J]. Hepatology,2010,52(4):1251-1257.
[11]
Piratvisuth T, Marcellin P, Popescu M, et al. Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients[J]. Hepatol Int,2011,7(2):429-436.
[12]
Moucari R, Mackiewicz V, Lada O, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients[J]. Hepatology,2009,49(4):1151-1157.
[13]
Brunetto MR, Moriconi F, Bonino F, et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B[J]. Hepatology,2009,49(4):1141-1150.
[14]
Ozaras R, Tabak F, Tahan V, et al. Correlation of quantitative assay of HBsAg and HBV DNA levels during chronic HBV treatment[J]. Dig Dis Sci,2008,53(11):2995-2298.
[15]
Wursthorn K, Jung M, Riva A, et al. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients[J]. Hepatology,2010,52(5):1611-1620.
[16]
Chen J, Wang Z, Guo Y, et al. Serum HBsAg changes in HBeAg positive chronic hepatitis B patients with continuous viral load reductions during treatment with adefovir or peg-interferon-alpha-2a[J]. Antiviral Res,2009,81(1):88-91.
[17]
Akuta N, Suzuki F, Kobayashi M, et al. Correlation between hepatitis B virus surface antigen level and alpha-fetoprotein in patients free of hepatocellular carcinoma or severe hepatitis[J]. J Med Virol,2014,86(1):131-138.
[18]
Liu J, Yang HI, Lee MH, et al. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study[J]. Gastroenterology,2010,139(2):474-482.
[19]
Chan HLY, Wong GLH, Tse CH, et al. Viral determinants of hepatitis B surface antigen seroclearance in hepatitis B e antigen-negative chronic hepatitis B patients[J]. J Infect Dis,2011,204(3):408-414.
[20]
Kobayashi M, Hosaka T, Suzuki F, et al. Seroclearance rate of hepatitis B surface antigen in 2,112 patients with chronic hepatitis in Japan during long-term follow-up[J]. J Gastroenterol,2014,49(3):538-546.
[21]
Brunetto MR, Oliveri F, Colombatto P, et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers[J]. Gastroenterology,2010,139(2):483-490.
[22]
Lin LY, Wong VW, Zhou HJ, et al. Relationship between serum hepatitis B virus DNA and surface antigen with covalently closed circular DNA in HBeAg-negative patients[J]. J Med Virol,2010,82(9):1494-1500.
[23]
Thompson AJ, Nguyen T, Iser D, et al. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis virus markers[J]. Hepatology,2010,51(6):1933-1944.
[24]
Janssen HL, Kerhof-Los CJ, Heijtink RA, et al. Measurement of HBsAg to monitor hepatitis B viral replication in patients on alpha-interferon therapy[J]. Antiviral Res,1994,23(3-4):251-257.
[1] 高建松, 陈晓晓, 冯婷, 包剑锋, 魏淑芳, 潘林. 基于超声瞬时弹性成像的多参数决策树模型评估慢性乙型肝炎患者肝纤维化等级[J]. 中华医学超声杂志（电子版）, 2023, 20(09): 923-929.
[2] 葛飞霞, 蒋银, 杨丹. 酶联免疫吸附测定法与PCR仪检测在乙型肝炎诊断中的临床应用[J]. 中华危重症医学杂志(电子版), 2023, 16(04): 310-315.
[3] 张小曼, 马筱秋, 许正锯, 张纯瑜, 何彩婷. 乙型肝炎病毒逆转录酶区耐药突变对血清乙型肝炎病毒表面抗原水平的影响[J]. 中华实验和临床感染病杂志(电子版), 2023, 17(05): 324-332.
[4] 王迎迎, 谢平. 乙型肝炎病毒感染合并肺结核患者发生肝损伤的危险因素及预测模型构建[J]. 中华实验和临床感染病杂志(电子版), 2023, 17(04): 267-273.
[5] 郑希彦, 周正, 何方平, 林志群, 杜飞, 谢琴, 王少平, 史宪杰. 代谢综合征与乙型肝炎病毒相关性肝细胞癌预后的危险因素分析[J]. 中华普通外科学文献(电子版), 2023, 17(02): 104-109.
[6] 吴方园, 孙霞, 林昌锋, 张震生. HBV相关肝硬化合并急性上消化道出血的危险因素分析[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 45-47.
[7] 范铁艳, 李君, 陈虹. 肝移植术后新发戊型病毒性肝炎的诊治经验[J]. 中华移植杂志(电子版), 2023, 17(05): 293-296.
[8] 雷雪雪, 于颖, 李虹彦. 乙型肝炎肝硬化患者肝移植等待期应用多模式预康复优化项目的临床研究[J]. 中华移植杂志(电子版), 2023, 17(03): 158-163.
[9] 陈淑钿, 梁韵, 廖媛, 王杨. 补体C3在HBV相关慢加急性肝衰竭患者预后评估中的价值[J]. 中华肝脏外科手术学电子杂志, 2023, 12(05): 562-566.
[10] 李勇, 兰川, 吴斌, 张光年, 李敬东. 术前血小板-白蛋白评分对肝硬化肝癌术后预后的预测价值[J]. 中华肝脏外科手术学电子杂志, 2023, 12(04): 412-416.
[11] 许语阳, 吕云福, 王葆春. 乙肝后肝硬化门静脉高压症脾肿大外科治疗进展[J]. 中华肝脏外科手术学电子杂志, 2023, 12(04): 469-473.
[12] 孔凡彪, 杨建荣. 肝脏基础疾病与结直肠癌肝转移之间关系的研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(07): 818-822.
[13] 许新强, 李雪松, 何伟业, 唐琼华. 2019年广州白云区医院监测点关于甲型流感和乙型流感流行情况分析[J]. 中华临床实验室管理电子杂志, 2023, 11(04): 230-234.
[14] 陈翀, 游冉冉, 王敏, 周豪杰. 单试剂HBsAg阳性、核酸检测阴性献血者的血液安全性评估[J]. 中华临床实验室管理电子杂志, 2023, 11(02): 95-98,104.
[15] 韦慧萍, 郭瑛明, 刘桂荣, 巫宗由, 翁秋青. 超氧化物歧化酶检测在乙型肝炎病毒相关性肝病中的应用价值[J]. 中华临床实验室管理电子杂志, 2023, 11(01): 21-26.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号